Prognostic significance of autoimmunity during treatment of melanoma with interferon
暂无分享,去创建一个
[1] J. Kirkwood,et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. , 2011, Seminars in immunopathology.
[2] J. Kirkwood,et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients , 2010, The Journal of experimental medicine.
[3] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[4] V. Sondak,et al. Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma , 2010, Cancer Chemotherapy and Pharmacology.
[5] David C. Smith,et al. Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. , 2010 .
[6] A. Eggermont,et al. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] P. Ascierto,et al. Melanoma: A model for testing new agents in combination therapies , 2010, Journal of Translational Medicine.
[8] A. Hauschild,et al. Pegylated interferons: prospects for the use in the adjuvant and palliative therapy of metastatic melanoma. , 2010, European journal of cancer.
[9] Shimon Sakaguchi,et al. Regulatory T cells exert checks and balances on self tolerance and autoimmunity , 2010, Nature Immunology.
[10] Jeffrey E Gershenwald,et al. Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] S. Almenar,et al. [Problems in defining melanoma regression and prognostic implication]. , 2009, Actas dermo-sifiliograficas.
[12] K. Drzewiecki,et al. Spontaneous regression of metastases from melanoma: review of the literature , 2009, Melanoma research.
[13] S. Aamdal,et al. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. , 2009, Journal of the National Cancer Institute.
[14] J. Kirkwood,et al. Does pegylated interferon α-2b confer additional benefit in the adjuvant treatment of high-risk melanoma? , 2009, Nature Clinical Practice Oncology.
[15] A. Hauschild,et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial , 2008, The Lancet.
[16] J. Kirkwood,et al. Interferon alfa-induced autoimmunity and serum S100 levels as predictive and prognostic biomarkers in high-risk melanoma in the ECOG-intergroup phase II trial E2696 , 2007 .
[17] D. Jukic,et al. Modulation of Signal Transducers and Activators of Transcription 1 and 3 Signaling in Melanoma by High-Dose IFNα2b , 2007, Clinical Cancer Research.
[18] K. Busam,et al. Primary Cutaneous Melanoma with Regression Does not Require a Lower Threshold for Sentinel Lymph Node Biopsy , 2007, Annals of Surgical Oncology.
[19] D. Pinkel,et al. Somatic activation of KIT in distinct subtypes of melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] D. Jukic,et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Martin A Weinstock,et al. Cutaneous melanoma: public health approach to early detection , 2006, Dermatologic therapy.
[22] A. Eggermont,et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial , 2005, The Lancet.
[23] A. Ribas,et al. Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma , 2005 .
[24] S. Sakaguchi. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self , 2005, Nature Immunology.
[25] G. Dranoff. CTLA-4 blockade: unveiling immune regulation. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] S. Groshen,et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] S. Sakaguchi,et al. Regulatory T Cells in Immunologic Self-Tolerance and Autoimmune Disease , 2005, International reviews of immunology.
[28] J. Manola,et al. A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma , 2004, Clinical Cancer Research.
[29] W. Greer,et al. Partial Regression of Primary Cutaneous Melanoma: Is There an Association with Sub-Clinical Sentinel Lymph Node Metastasis? , 2003, The American Journal of dermatopathology.
[30] H. Ochs,et al. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis , 2003, Current opinion in rheumatology.
[31] Thomas A. Davis,et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[32] S. Hori,et al. Control of autoimmunity by naturally arising regulatory CD4+ T cells. , 2003, Advances in immunology.
[33] E. Herrmann,et al. Pharmacokinetics of Peginterferons , 2003, Seminars in liver disease.
[34] J. Kirkwood,et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[36] F. Powrie,et al. Control of intestinal inflammation by regulatory T cells. , 2001, Microbes and infection.
[37] N Cascinelli,et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] S. Steinberg,et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] V. Sondak,et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] M. Manns,et al. Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C , 2001, Gut.
[41] V. Sondak,et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] G. Brabant,et al. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] A. Caraceni,et al. Neurotoxicity of interferon‐α in melanoma therapy , 1998 .
[44] K. Kälkner,et al. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. , 1998, QJM : monthly journal of the Association of Physicians.
[45] B. Williams,et al. Signal transduction in the interferon system. , 1998, Seminars in oncology.
[46] A. Caraceni,et al. Neurotoxicity of interferon-alpha in melanoma therapy: results from a randomized controlled trial. , 1998, Cancer.
[47] P. Yeo,et al. Interferon-α Induced Thyroid Dysfunction: Three Clinical Presentations and a Review of the Literature , 1997 .
[48] A. Horsch,et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy , 1997, Hepatology.
[49] P. Yeo,et al. Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. , 1997, Thyroid : official journal of the American Thyroid Association.
[50] J. Kirkwood,et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] I. Jackson,et al. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. , 1996, Human molecular genetics.
[52] T. Okanoue,et al. Side effects of high-dose interferon therapy for chronic hepatitis C. , 1996, Journal of hepatology.
[53] S. Rosenberg,et al. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[54] G. Martinelli,et al. Autoimmune mediated thrombocytopenia associated with the use of interferon-alpha in chronic myeloid leukemia. , 1996, Haematologica.
[55] S. Steinberg,et al. Thyroid Dysfunction in 281 Patients with Metastatic Melanoma or Renal Carcinoma Treated with Interleukin‐2 Alone , 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[56] G. Lutfalla,et al. α and α Interferons and Their Receptor and Their Friends and Relations , 1995 .
[57] L. Cavanna,et al. Autoimmune thyroid dysfunctions in hematologic malignancies treated with alpha-interferon. , 1995, Acta haematologica.
[58] G. Lutfalla,et al. Alpha and beta interferons and their receptor and their friends and relations. , 1995, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[59] L. Naldi,et al. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma , 2006 .
[60] J. Darnell,et al. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. , 1994, Science.
[61] J. Becker,et al. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma , 1994, Cancer.
[62] N. Weijl,et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] K. Schallreuter,et al. Vitiligo and cutaneous melanoma. A case study. , 1991, Dermatologica.
[64] P. Carlini,et al. Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma. , 1990, European journal of cancer.
[65] M. Atkins,et al. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. , 1988, The New England journal of medicine.
[66] J. Kirkwood,et al. A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] A. Kopf,et al. Prognostic significance of hypopigmentation in malignant melanoma. , 1987, Archives of dermatology.
[68] D. Ahmann,et al. Phase II study of recombinant leukocyte a interferon (rIFN‐αA) in disseminated malignant melanoma , 1984, Cancer.
[69] D. Ahmann,et al. Phase II study of recombinant leukocyte A interferon (rIFN-alpha A) in disseminated malignant melanoma. , 1984, Cancer.
[70] J. Kirkwood,et al. Vitiligo in patients with metastatic melanoma: a good prognostic sign. , 1983, Journal of the American Academy of Dermatology.
[71] A. Kopf,et al. Inhibition of growth of B16 murine malignant melanoma by exogenous interferon. , 1980, Cancer research.
[72] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[73] D.,et al. Regression Models and Life-Tables , 2022 .